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Abstract Treatment of a symptomatic stenosis is known to
be most beneficial within 14 days after the presenting event
but this can frequently not be achieved in daily practice. The
aim of this study was the assessment of factors responsible
for this time delay to treatment. A retrospective analysis of a
prospective two-center CAS database was carried out to
investigate the potential factors that influence a delayed CAS
treatment. Of 374 patients with a symptomatic carotid ste-
nosis, 59.1% were treated beyond C14 days. A retinal TIA
event (OR = 3.59, 95% CI 1.47–8.74, p \ 0.01) was found
to be a predictor for a delayed treatment, whereas the year of
the intervention (OR = 0.32, 95% CI 0.20–0.50, p \ 0.01)
and a contralateral carotid occlusion (OR = 0.42, 95% CI
0.21–0.86, p = 0.02) were predictive of an early treatment.
Similarly, within the subgroup of patients with transient
symptoms, the year of the intervention (OR = 0.28, 95% CI
0.14–0.59, p \ 0.01) was associated with an early treatment,
whereas a retinal TIA as the qualifying event (OR = 6.96,
95% CI 2.37–20.47, p \ 0.01) was associated with a delayed
treatment. Treatment delay was most pronounced in patients
with an amaurosis fugax, whereas a contralateral carotid
occlusion led to an early intervention. Although CAS is
increasingly performed faster in the last years, there is still
scope for an even more accelerated treatment strategy, which
might prevent future recurrent strokes prior to treatment.
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Introduction
In the past few years, several population-based studies have
clearly demonstrated that patients with a transient ischemic
attack (TIA) or stroke have a high risk for a subsequent
stroke [6]. Based on a six or seven-point score, using age,
blood pressure, diabetes mellitus, clinical features, and
duration of symptoms, the risk of further ischemic symp-
toms appears to be highly predictable, ranging from 3.1 to
17.8% at 90 days (ABCD and ABCD2 score) [11, 17]. In
addition, evidence has accumulated that TIA or mild-stroke
patients with a large-artery atherosclerosis have a particu-
larly high risk of early recurrent stroke, which reaches up
to 28% within 14 days [14, 15]. Moreover, an early carotid
endarterectomy (CEA) has been shown to be associated
with a beneficial outcome in contrast to an intervention
beyond 12 weeks after the qualifying ischemic event,
which was found to have only a minimal effect for sec-
ondary stroke prevention [16]. Current updated guidelines
therefore recommend that a CEA should ideally be
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performed within 2 weeks of a presenting event [3, 18].
Despite these recommendations, CEA is often delayed for
weeks to months [5] due to logistic reasons or a resource
shortage, indicating that it might be difficult to translate
this ambitious goal into everyday practice on the short
term. In a recently published interim-analysis of the GALA
Trial, a multicenter randomized trial of general versus local
anesthesia during CEA, the median delay between symp-
toms and surgery was 82 days [4]. Similar time delays
between presenting event and CEA have been reported in
other population-based surveys across different countries
[7, 8, 10].
Lately, carotid artery stenting (CAS) has increasingly
been used as a treatment alternative to CEA, and it is
unlikely that the majority of patients are currently treated
with CAS within 2 weeks of their symptomatic event. In
fact, within the recently published Pro-CAS register and
the ICSS study, only about 25% of the patients had been
treated within the recommended time frame of 14 days [9,
19]. In order to increase the benefit of secondary stroke
prevention by reducing the time delay between symptoms
and carotid revascularization procedures, it is thus crucial
to identify the procedural or clinical features that are
associated with a delayed intervention. With the knowledge
of these factors, further awareness campaigns of the gen-
eral population can be initiated and a fast-track medical
management program can be pursued in patients having a
high risk of subsequent stroke.
We used our prospective CAS database to determine
which clinical factors were associated with a delayed
treatment (i.e., C14 days) and which part of the investi-
gation logistics was responsible for this treatment delay.
Methods
Study population
From January 2001 to December 2009, a total of 374
patients with symptoms due to a high-grade carotid ste-
nosis were treated with CAS at two university hospitals
following a prospective protocol (University of Tu¨bingen
n = 220, University of Go¨ttingen n = 154). Patients were
recruited from the in-hospital emergency department
where patients presented by themselves or were admitted
by the local practitioner or neurologist, the local ambu-
lance, or by admission from regional hospitals. The
symptoms of the qualifying event were either classified as
an ischemic stroke, an ipsilateral transient ocular, or as a
contralateral transient hemispheric cerebral event with
respect to the side of the carotid stenosis. In patients with
transient symptoms, the qualifying event had resolved
completely within 24 h. The symptomatic event had
occurred during the last 180 days prior to treatment and
patients had to be in clinically stable conditions. All
patients had a high-grade carotid stenosis C70% as
assessed with sonography according to the European
guidelines to estimate the degree of stenosis [2] and the
grade of stenosis was confirmed angiographically during
the stenting procedure.
All patients were informed about the different treatment
modalities (CEA, CAS, and best medical treatment) and
their specific risks. With respect to the CAS procedure, all
patients were informed about the investigational nature of
CAS and gave their written informed consent. This study
was approved by the local Ethics Review Board.
Data collection
The following cerebrovascular risk factors were recorded
using history or direct measurements: hypertension (blood
pressure C140/90 mmHg measured on repeated occasions
or presence of antihypertensive drugs), diabetes mellitus
(HbA1c [6.5%, fasting blood glucose [120 mg/dl, or
presence of antidiabetic drugs), hyperlipidemia (fasting
serum cholesterol levels [220 mg/dl or statin therapy),
smoking (current or within the previous year), coronary
artery disease (history of angina, myocardial infarction,
percutaneous transluminal angioplasty or surgery) and the
presence of contralateral carotid disease (as assessed with
ultrasound).
The following time intervals were recorded: (1) days
between symptom onset and the carotid ultrasound proce-
dure; (2) between symptom onset and hospital admission;
(3) the length of the hospital stay; and (4) days between
hospital admission and CAS procedure. Time delay to CAS
was defined as the period between the first clinical symp-
toms attributable to the corresponding carotid stenosis and
the CAS procedure. A subsequent neurological symptom
was scored as an additional recurrent symptom and time
intervals were referenced to the day of the first clinical
symptom. The duration and the clinical symptoms of the
transient symptomatic event and the NIH-SS before the
intervention were registered. If a pathological carotid
ultrasound finding from an outside hospital or practitioner
was verified during hospitalization with locally adopted
criteria, the date of the first external ultrasound was
recorded for further assessments. All patients were treated
by a neurologist with experience in neurovascular diseases.
The ABCD score was derived for patients with transient
symptoms as follows: age [ 60 years = 1, elevated blood
pressure ([140 mmHg systolic and/or [90 mmHg dia-
stolic) = 1, clinical features of presenting event (unilateral
weakness = 2, speech disturbance without weakness = 1,
other = 0), and duration of clinical symptoms in minutes
(C60 = 2, 10–59 = 1, \10 = 0) [17]. One additional
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point was added for the presence of diabetes mellitus to
calculate the ABCD2 score [11]. The periprocedural 30d
complications following CAS were recorded and catego-
rized as minor- (a new neurological deficit that either
resolved completely within 7 days or increased the NIH
Stroke Scale score by B3) major stroke (a new neurological
deficit that persisted after 7 days and increased the NIH
Stroke Scale score by C4) or death (death of any cause).
Statistical analysis
Continuous values were expressed as mean ± standard
deviation (SD) and nominal variables as count and per-
centages, not normally distributed ordinal values as median
values with the corresponding interquartile range (IQR),
respectively. For comparisons of categorical data, two-
tailed Chi-square statistics with Yates correction and uni-
variate Fisher’s exact test were used. The Fisher’s exact
test was used when the predicted contingency table cell
values were less than five. Ordinal data were compared
using a Mann–Whitney U test.
Imbalanced variables with respect to time delay to CAS
were identified on the basis of the univariate level if the
p value reached a value below 0.1. A multiple logistic
regression analysis was applied to determine the indepen-
dence of the imbalanced variables. Interaction was assessed
by using additive and multiplicative interaction terms.
Results are presented as odds ratio with 95% confidence
interval.
A bivariate correlation analysis (Kendall’s tau-b) was
applied to investigate the interrelation of treatment delay
and the year of intervention.
A two-sided p value of less than 0.05 was considered to
indicate a statistically significant difference. All statistical
analyses were performed using SPSS (Version 17, SPSS
inc., Chicago, IL).
Results
The study population comprised a total of 374 patients
(mean age 69.1 ± 9.2 years, 269 men, 105 women) with a
symptomatic carotid stenosis. For the entire study popu-
lation, the median time delay between clinical symptoms
and CAS was 20 days (IQR 10–37). A total of 153 patients
(40.9%) were treated within 14 days (8, IQR 6–11),
whereas 221 (59.1%) patients received their intervention
beyond 2 weeks (median: 34, IQR 22–57). A total of 189
(50.0%) patients presented with an ischemic stroke and 185
(49.5%) with transient symptoms; 143 (38.2%) of these
patients had transient hemispherical symptoms and 49
(13.1%) patients had transient ocular symptoms,
respectively.
The baseline characteristics of the patients treated
beyond and within 14 days and the results of the univariate
analyses are summarized in Table 1.
Patients treated beyond 14 days from symptom onset to
CAS received their carotid ultrasound later (29.4 vs.
2.5 days, p \ 0.01) and were admitted to the hospital with a
significantly longer time delay than patients treated with
14 days (37.7 vs. 2.2 days, p \ 0.01). The time from hos-
pital admission to CAS was also significantly longer in
patients treated beyond 14 days (7.7 vs. 5.8 days, p \ 0.05).
Patients treated beyond 14 days had a lower NIHSS (2.9
vs. 3.4, p \ 0.05) and more often had a transient ocular
event (19 vs. 4.6%, p \ 0.01) than patients treated within
14 days, whereas a contralateral occlusion was found more
often (16.3 vs. 7.2%, p \ 0.01) among the early treated
patients. The latter patients also had more recurrent neu-
rological symptoms (11.7 vs. 5.9%, p = 0.04) before the
CAS procedure.
Clinical complication rates after CAS (minor stroke,
major stroke, and death within 30 days; 7.8 vs. 8.1%,
p = 1.0), as well as hospitalization days (11.7 vs. 11.7,
p = 0.94) did not differ between these groups (see Table 1).
In order to calculate the ABCD and ABCD2 scores in a
subgroup of patients with transient symptoms, the duration
of the clinical symptoms was divided into three groups
(\10, 10–59 and C60 min). Within the subgroup of patients
with transient symptoms, subjects treated beyond 14 days
more frequently had an ocular event than a hemispherical
TIA (62.5 vs. 90.4%, p \ 0.01), a lower ABCD and ABCD2
score [3 (IQR 2–4) vs. 4 (IQR 3–4.5), p \ 0.01; 3 (IQR 2–4)
vs. 4 (IQR 3–5), p \ 0.01] and a shorter duration of their
initial clinical symptoms (\10 min 64.3 vs. 32.9%,
p \ 0.01), whereas subjects with long transient clinical
symptoms (C60 min) were more often treated within
14 days (41.1 vs. 17.0%, p \ 0.01). The proportion of
patients in the subgroup treated beyond 14 days was lower
after the year 2004 (24.1 vs. 53.4%, p \ 0.01).
After applying multiple logistic regression analysis and
adjusting for variables that were imbalanced between both
groups (contralateral ICA occlusion, hemispherical or
ocular TIA, NIH-SS before CAS, recurrent symptomatic
event and intervention after the year 2004), a retinal TIA
event (OR = 3.59, 95% CI 1.47–8.74, p \ 0.01) remained
the only significant variable that was useful for predicting a
delayed treatment beyond 14 days, whereas the year of the
intervention (OR = 0.32, 95% CI 0.20–0.50, p \ 0.01) and
a contralateral carotid occlusion (OR = 0.42, 95% CI
0.21–0.86, p = 0.02) were predictive of an early treatment.
Similarly, the year of the intervention (OR = 0.28, 95% CI
0.14–0.59, p \ 0.01) was associated with early treatment,
whereas a retinal TIA as the qualifying event (OR = 6.96,
95% CI 2.37–20.47, p value of p \ 0.01) was associated
with a delayed treatment within the subgroup of patients
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with transient symptoms after adjustment for imbalanced
variables (retinal TIA, ABCD and ABCD2 score, duration
of symptoms C60 and \10 min, year of intervention
[2004). Bivariate correlation analysis revealed a signifi-
cant negative association between the treatment delay and
the year of the CAS intervention (correlation coeffi-
cient = -0.22, p \ 0.001, Fig. 1).
Discussion
In this paper we assessed the time delay between a
symptomatic qualifying event due to a high-grade carotid
artery stenosis and subsequent CAS treatment in order to
identify factors contributing to a deferred stenting proce-
dure which might reduce the benefit of this secondary
Table 1 Patient characteristics (n = 374)
Time delay to intervention
\14 days C14 days p value
n 153 (40.9%) 221 (59.1%)
Mean age (years) 68.8 (±9.6) 69.3 (±8.9) 0.59
Age C 80 years 24 (15.7%) 29 (13.1%) 0.48
Male 115 (75.2%) 154 (70.0%) 0.27
Sympt. event—CAS (days) 8.0 (±3.2) 45.8 (±34.9) \0.01
Sympt. event—carotid ultrasound (days) 2.5 (±2.8) 29.4 (±46.8) \0.01
Sympt. event—hospital admission (days) 2.2 (±3.2) 37.7 (±37.4) \0.01
Hospital admission—CAS (days) 5.8 (±3.3) 7.7 (±8.6) 0.01
Hospitalization (days) 11.7 (±6.0) 11.7 (±8.1) 0.94
Cerebrovascular risk factors
Hypertension 130 (85.0%) 185 (83.7%) 0.74
Hyperlipidemia 95 (62.1%) 135 (61.1%) 0.84
Tobacco use 50 (32.7%) 68 (30.8%) 0.65
Coronary artery disease 53 (34.6%) 62 (28.1%) 0.33
Diabetes mellitus 45 (29.4%) 69 (31.2%) 0.71
Lesion characteristics
Degree of stenosis (%) 82.0 (±9.4) 82.2 (±9.0) 0.76
Contralateral ICA occlusion 25 (16.3%) 16 (7.2%) \0.01a,b
Contralateral ICA stenosis [70% 16 (10.5%) 23 (10.4%) 0.76
Clinical presentation and complications
Ischemic stroke 80 (52.3%) 109 (49.3%) 0.59
Hemispherical TIA 66 (43.1%) 70 (31.7%) 0.02a
Retinal TIA 7 (4.6%) 42 (19.0%) \0.01a,b
NIHSS before CAS 3.4 (±2.6) 2.9 (±2.4) 0.02a
Recurrent symptoms before CAS 18 (11.7%) 13 (5.9%) 0.04a
Intervention C year 2005 94 (61.4%) 74 (33.5%) \0.01a,b
Periprocedural complications (mmd) 12 (7.8%) 18 (8.1%) 1.00
Subgroup of patients with transient symptoms (n = 185)
n 73 (39.5%) 112 (60.5%)
Hemispherical TIA 66 (90.4%) 70 (62.5%) \0.01a
Retinal TIA 7 (9.5%) 42 (37.5%) \0.01a
ABCD score 4 (IQR 3–4.5) 3 (IQR 2–4) \0.01a
ABCD2 score 4 (IQR 3–5) 3 (IQR 2–4) \0.01a
Duration of symptoms C60 min 30 (41.1%) 19 (17.0) \0.01a
10–60 min 19 (26.0%) 21 (18.8%) 0.24
\10 min 24 (32.9%) 72 (64.3%) \0.01a
Intervention C year 2005 39 (53.4%) 27 (24.1%) \0.01a,b
a Factors included in multiple regression analysis
b Factors remained significant after multiple regression analysis
mmd minor-, major stroke and death
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stroke prevention. Within this prospective study of two
university centers, treatment was delayed C14 days in the
majority (59%) of patients. Independent clinical factors,
which were associated with a delayed treatment, were a
retinal TIA as a qualifying event and a treatment before the
year 2005, whereas the presence of a contralateral carotid
occlusion was significantly associated with an early treat-
ment. Similar results were found for the subgroup of
patients who had presented with transient symptoms.
Finally, the presence of a high ABCD- or of a high ABCD2
score did not influence the time delay to treatment.
Large artery atherosclerosis is the most meaningful
cause for early stroke recurrence after a TIA or minor
stroke [13]. This finding is thought to be caused by an
ongoing embolic process of the carotid artery originating
from a ruptured vulnerable plaque. Early carotid surgery is
not associated with a higher rate of periprocedural com-
plications [16] than delayed surgery in clinical stable
patients. Similarly, and in good agreement with our current
results, large registries indicate that the timing of CAS does
not influence the outcome [19]. Moreover, the benefit of a
delayed CEA treatment vanishes over time and may even
be absent for certain patient subgroups if carried out
beyond 3 months [16]. Therefore, current guidelines rec-
ommend an early carotid revascularization (ideally within
14 days) in patients with a recently symptomatic carotid
stenosis [3, 18]. However, despite these recommendations,
numerous patients are currently still being treated with
either CEA or CAS beyond the recommended 14-day time
interval [4, 5, 7, 8, 10], indicating a possible shortage of
resources or difficulties to implement these guidelines into
daily routine. In this study, many patients were also treated
beyond the proposed 14-day time frame with CAS. This
finding is in line with recently published data of the Pro-
CAS registry [19]. In fact, only 26% (609 of 2,344) of
patients with a symptomatic carotid artery stenosis were
treated within 14 days within this prospective multicenter
registry. Likewise, within the lately published ICSS study
in which the efficacy of CAS or CEA for treating a
symptomatic carotid stenosis was randomly investigated,
only 25% of patients in the CAS and 18% in the CEA
group were treated within 14 days [9].
To obtain a faster treatment in the future, our data cor-
roborate the need for an accelerated admittance strategy.
As delineated in Table 1, most of the treatment delay was
due to either the delayed referral to an ultrasound exami-
nation of the carotid arteries or to the hospital admittance
itself. In contrast, the times from hospital admittance to
CAS, as well as the total hospitalization times did not have
a major impact on a delayed treatment. The in-hospital
patient management only marginally contributes to the
delayed treatment, which might for instance be attributable
to a risk of reperfusion hemorrhages in patients with a
high-grade carotid stenosis. Although we are unable to
differentiate between patient-related and non-patient-rela-
ted factors contributing to the pre-hospitalization times, it
is likely that a combination of these factors leads to a
delayed referral and thus treatment in many patients. On
the one hand, patients themselves, especially those with a
TIA, may delay seeking medical attention. At least indi-
rectly, this assumption is supported by our observation that
patients with more severe transient or permanent neuro-
logical deficits were treated in a more timely fashion than
those for instance with an isolated amaurosis fugax.
On the other hand, patients often primarily present to
their local practitioners, who might delay referral to the
hospital or to physicians with expertise in carotid ultra-
sound. As outlined in Fig. 1, there was an ongoing rise of
the proportion of patients being treated early, reaching
nearly 80% in the year 2009. Therefore, it seems to be
possible to treat the vast majority of patients in a timely
fashion and that this has been increasingly implemented
during the last years.
A contralateral ICA occlusion was significantly associ-
ated with a treatment within 14 days. This may be related
to earlier results of the NASCET-data in which these
patients carried a very high risk for further strokes [1]. At
least within our patient cohort this fact seems to have
already been integrated into daily practice.
The usefulness of the ABCD and ABCD2 score in
patients with transient symptoms could recently be shown
to predict the individual patient risk for subsequent strokes
[11, 17, 20]. Although a higher score was found more
frequently in the group of patients treated within 2 weeks,
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Fig. 1 Proportion of patients treated\14 days (grey) and 14 or more
days (black) according to the year of the CAS intervention. Within the
years there was a significant trend to treat the majority of patients in a
more timely fashion (correlation coefficient = -0.22, p \ 0.001)
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treated beyond this crucial time frame. Taking into account
the proposed high risk for stroke recurrence in patients with
transient symptoms due to a carotid stenosis and high
ABCD/ABCD2 scores [12], these results clearly support
the notion that further awareness campaigns for the general
population, as well as for general practitioners need to be
initiated.
We acknowledge that our study has several limitations.
Despite the fact that these data were acquired in a pro-
spective manner, parts of the analysis were done in a ret-
rospective fashion. Although primary outcome parameters
were not imbalanced between the centers, it is not possible
to definitely rule out a potential selection bias of slightly
different CAS protocols, patient selection, admittance
practices, and patient management during the pre-hospi-
talization phase.
In conclusion, in this study we could show that many
patients with a symptomatic carotid stenosis are currently
still being treated with CAS beyond the recommended time
frame of 2 weeks after their presenting ischemic event. In
addition to a delayed admittance to the hospital, treatment
delay was most pronounced in patients with an amaurosis
fugax, whereas a contralateral carotid occlusion led to an
early intervention. Although CAS was performed more
quickly in the last years, there is still scope for an even
more accelerated treatment strategy, which might prevent
recurrent strokes prior to treatment.
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